Arthur Ryan - Regeneron Pharmaceuticals Independent Director
| REGN Stock | USD 907.32 7.16 0.80% |
Director
Mr. Arthur F. Ryan is an Independent Director of the Company. Mr. Ryan retired as the Chairman of the Board of Prudential Financial, Inc., one of the largest diversified financial institutions in the world. He served as Chief Executive Officer of Prudential until December 2007. Prior to joining Prudential in December 1994, Mr. Ryan served as President and Chief Operating Officer of Chase Manhattan Bank since 1990 since 2003.
| Age | 75 |
| Tenure | 21 years |
| Address | 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 |
| Phone | 914 847 7000 |
| Web | https://www.regeneron.com |
Arthur Ryan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Arthur Ryan against Regeneron Pharmaceuticals stock is an integral part of due diligence when investing in Regeneron Pharmaceuticals. Arthur Ryan insider activity provides valuable insight into whether Regeneron Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Regeneron Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Regeneron Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Arthur Ryan over a month ago Disposition of tradable shares by Arthur Ryan of Regeneron Pharmaceuticals at 986.58 subject to Rule 16b-3 |
Regeneron Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0849 % which means that it generated a profit of $0.0849 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1626 %, meaning that it created $0.1626 on every $100 dollars invested by stockholders. Regeneron Pharmaceuticals' management efficiency ratios could be used to measure how well Regeneron Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Tangible Assets is likely to grow to 0.13. Also, Return On Capital Employed is likely to grow to 0.14. At this time, Regeneron Pharmaceuticals' Net Tangible Assets are very stable compared to the past year. As of the 24th of April 2024, Return On Tangible Assets is likely to grow to 0.13, while Other Current Assets are likely to drop about 203.9 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Michael Grey | Biomarin Pharmaceutical | 65 | |
| Carl Gordon | Intellia Therapeutics | 52 | |
| Alec Machiels | Apellis Pharmaceuticals | 45 | |
| Donald Glazer | BeiGene | 72 | |
| Richard Levy | Madrigal Pharmaceuticals | 60 | |
| Ronald Renaud | PTC Therapeutics | 45 | |
| Kathryn Falberg | Biomarin Pharmaceutical | 54 | |
| Mette Jensen | Novo Nordisk AS | 45 | |
| Judy Olian | United Therapeutics | 66 | |
| Margaret Hamburg | Alnylam Pharmaceuticals | 62 | |
| William Aliski | Ultragenyx | 70 | |
| Kenneth Bate | Madrigal Pharmaceuticals | 67 | |
| Anthony Chase | Sarepta Therapeutics | 60 | |
| JeanPaul Kress | Sarepta Therapeutics | 49 | |
| Dennis Slamon | Biomarin Pharmaceutical | 68 | |
| Elizabeth Anderson | Biomarin Pharmaceutical | N/A | |
| Phillip Sharp | Alnylam Pharmaceuticals | 73 | |
| Frederick Craves | Madrigal Pharmaceuticals | 72 | |
| Laurence Debroux | Novo Nordisk AS | 51 | |
| Pablo Cagnoni | Crispr Therapeutics AG | 55 | |
| Joseph Wender | Ionis Pharmaceuticals | 73 | |
Management Performance
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.0849 |
Regeneron Pharmaceuticals Leadership Team
Elected by the shareholders, the Regeneron Pharmaceuticals' board of directors comprises two types of representatives: Regeneron Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Regeneron. The board's role is to monitor Regeneron Pharmaceuticals' management team and ensure that shareholders' interests are well served. Regeneron Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Regeneron Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles Baker, Independent Director | ||
| Joseph Goldstein, Independent Director | ||
| Anthony Coles, Independent Director | ||
| Patrice Gilooly, Senior Operations | ||
| Christopher CPA, Head Finance | ||
| George Sing, Independent Director | ||
| Gerald Underwood, Senior Operations | ||
| Peter Powchik, Senior Vice President - Clinical Development | ||
| Jay Markowitz, Senior Vice President - Portfolio Management | ||
| Robert Terifay, Sr. VP of Commercial | ||
| Robert Landry, CFO and Sr. VP of Fin. | ||
| Michael Brown, Independent Director | ||
| Ryan Crowe, Senior Analysis | ||
| Christine Poon, Independent Director | ||
| Neil Stahl, Executive VP of RandD | ||
| Marion McCourt, Senior Vice President and Head of Commercial | ||
| George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director | ||
| Andrew Murphy, Executive Research | ||
| Huda Zoghbi, Director | ||
| Bonnie Bassler, Director | ||
| Joseph LaRosa, Senior Vice President General Counsel, Secretary | ||
| Bob McCowan, Senior Officer | ||
| Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply | ||
| Leonard Schleifer, President CEO, Director | ||
| Alfred Gilman, Independent Director | ||
| Roy Vagelos, Chairman of the Board | ||
| Michael Aberman, Vice President - Strategy | ||
| Manisha Narasimhan, IR Contact | ||
| Douglas McCorkle, Vice President Controller, Assistant Treasurer | ||
| Marc TessierLavigne, Independent Director | ||
| Christopher Fenimore, Vice President Controller | ||
| Arthur Ryan, Independent Director |
Regeneron Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Regeneron Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.0849 | ||||
| Profit Margin | 0.30 % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 89.45 B | ||||
| Shares Outstanding | 107.94 M | ||||
| Shares Owned By Insiders | 2.58 % | ||||
| Shares Owned By Institutions | 89.29 % | ||||
| Number Of Shares Shorted | 1.42 M | ||||
| Price To Earning | 15.51 X |
Currently Active Assets on Macroaxis
When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for Regeneron Stock analysis
When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.03) | Earnings Share 34.73 | Revenue Per Share 122.935 | Quarterly Revenue Growth 0.006 | Return On Assets 0.0849 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.